Amyris - AMRS Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRS, but not buy additional shares or sell existing shares.
View AMRS analyst ratings or view top-rated stocks.

3 brokerages have issued 1-year price targets for Amyris' stock. Their AMRS share price forecasts range from $4.00 to $19.00. On average, they expect the company's stock price to reach $12.67 in the next twelve months. This suggests a possible upside of 333.8% from the stock's current price.
View analysts price targets for AMRS or view top-rated stocks among Wall Street analysts.

Amyris' stock was trading at $5.41 at the beginning of the year. Since then, AMRS shares have decreased by 46.0% and is now trading at $2.92.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AMRS earnings forecast.

Amyris, Inc. (NASDAQ:AMRS) issued its quarterly earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.06. The biotechnology company had revenue of $65.20 million for the quarter, compared to analyst estimates of $81.53 million. Amyris's revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.16) earnings per share.

Amyris shares reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

84 employees have rated Amyris Chief Executive Officer John Melo on Glassdoor.com. John Melo has an approval rating of 54% among the company's employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Amyris to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia Oyj (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Shares of AMRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMRS stock can currently be purchased for approximately $2.92.

Amyris (NASDAQ:AMRS) has a market capitalization of $944.44 million and generates $341.82 million in revenue each year. The biotechnology company earns $-270,970,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.

The company employs 980 workers across the globe.

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The official website for the company is amyris.com. The biotechnology company can be reached via phone at (510) 450-0761, via email at investor@amyris.com, or via fax at 510-225-2645.